Third Harmonic Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THRD research report →
Range $3.6 – $23
Price Chart
About the company
Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT.
- CEO
- Natalie C. Holles
- IPO
- 2022
- Employees
- 31
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on THRD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $242.79M
- P/E
- 4.94
- PEG
- -0.11
- P/S
- 0.00
- P/B
- 0.79
- EV/EBITDA
- 0.86
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 16.41%
- ROIC
- 20.42%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-49,000-40.0%
- Op Income
- $58.87M
- Net Income
- $45.47M+247.5%
- EPS
- $1.09+239.7%
- OCF Growth
- -68.9%
- FCF Growth
- -67.6%
- 52W High
- $16.02
- 52W Low
- $3.18
- 50D MA
- $5.38
- 200D MA
- $7.01
- Beta
- 2.13
- RSI (14)
- 44
- Avg Volume
- 262.78K
No earnings-call transcripts are available for THRD yet.
- Free Float
- 49.4%
- Shares Outstanding
- 45.13M
- Float Shares
- 22.29M
of shares held by institutions
110 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Boxer Capital, LLC | 2.00M | 0 |
| Blackrock Inc. | 1.43M | ▲ 65.78K |
| Nuveen Asset Management, LLC | 37.25K | 0 |
Held by 52 ETFs
Biggest fund positions in THRD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 11, 25 | Holles Natalie C. | other | 998,854 |
| Aug 11, 25 | Holles Natalie C. | other | 50,000 |
| Aug 11, 25 | Holles Natalie C. | other | 1,218,836 |
| Aug 11, 25 | Gladstone Michael | other | 43,584 |
| Aug 11, 25 | Murphy Christopher M. | other | 47,500 |
| Aug 11, 25 | Iwicki Mark T | other | 83,296 |
| Aug 11, 25 | Iwicki Mark T | other | 128,631 |
| Aug 11, 25 | Seidel Hans Martin | other | 85,753 |
| Aug 11, 25 | Seidel Hans Martin | other | 53,090 |
| Aug 11, 25 | Soloway Thomas P | other | 120,166 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our THRD coverage
Recent articles, reports, and earnings notes.
No research on THRD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate THRD report →Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
globenewswire.com · Jun 12
Third Harmonic Bio Announces Plan of Liquidation and Dissolution
globenewswire.com · Apr 14
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results
globenewswire.com · Mar 27
Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com · Mar 4
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Feb 14
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)
zacks.com · Feb 14
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
benzinga.com · Feb 12
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
globenewswire.com · Feb 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.